Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 4 1

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 2Endocrine 1

Conditions

Carcinoma, Medullary 4Neoplasm Metastasis 3Thyroid Neoplasms 2Recurrence 1Neoplasms 1Familial medullary thyroid carcinoma 1

Interventions

selpercatinib 5vandetanib 4cabozantinib 4Magnetic Resonance Spectroscopy 3Specimen Handling 2fluorodopa F 18 1fludarabine 1cemiplimab 1Thyroidectomy 1Standard of Care 1Practice Guidelines as Topic 1Nivolumab 1Neck Dissection 1Interviews as Topic 1High-Energy Shock Waves 1Fluorodeoxyglucose F18 1FAPI-46 1Decision Support Techniques 1Cyclophosphamide 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Carcinoma, Medullary × vandetanib × 1 year × Clear all
NCT01298323 2026-04-17

Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

Sanofi

Phase 3 Completed
205 enrolled 10 charts

Neoplasm Metastasis, Carcinoma, Medullary

NCT04211337 2026-03-19

LIBRETTO-531

Eli Lilly and Company

Phase 3 Active not recruiting
291 enrolled 16 charts 1 FDA

Carcinoma, Medullary

NCT01496313 2025-10-03

To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer

Sanofi

Phase 4 Completed
81 enrolled 15 charts
Head & Neck

Neoplasm Metastasis, Thyroid Neoplasms, Carcinoma, Medullary

NCT00410761 2025-09-24

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Sanofi

Phase 3 Completed
331 enrolled 15 charts
EndocrineHead & Neck

Familial medullary thyroid carcinoma, Thyroid Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡